Investments are the engine of long-term wealth. As markets change, so should your portfolio. Learn more: https://t.co/vunGJVsfpb (Photo: Alfred Gescheidt via Getty Images) https://t.co/THLJMSTqff ...

What's your longest-held token in your portfolio? ...

Core Viewpoint - Elanco Animal Health is entering a new phase focused on sustainable growth, margin expansion, and a stronger balance sheet, as outlined during its first Investor Day in five years [1] Financial Outlook - Elanco projects mid-single-digit organic revenue growth, high-single-digit adjusted EBITDA growth, and low-double-digit adjusted EPS growth starting in 2026 [2] - The company anticipates free cash flow of at least $1 billion from 2026 to 2028, with net leverage expected to fall below 3x in 2027, targeting a long-term range of 2.0x to 2.5x [2] R&D Investments - Elanco plans to expand R&D operations in Indianapolis and increase its U.S.-based manufacturing footprint, including investments in its Kansas monoclonal antibody facility [3] - The company is progressing towards final USDA approval for Befrena, a potential blockbuster dermatitis treatment for dogs, with a launch expected in the first half of 2026 [4] - Elanco forecasts approximately $1.1 billion in revenue from its innovation portfolio in 2026, an increase from prior expectations for 2025 [4] - The company has expanded its focus to eight innovation areas and added two new internal development platforms in monoclonal antibodies and immunotherapy [4] - More than 10 major pipeline programs are expected to carry blockbuster potential, with approvals anticipated for five to six differentiated assets between 2026 and 2031 [5] Cost Initiatives - Elanco detailed its Ascend productivity initiative, expecting $25 million in savings in 2026 and $60 million in 2027, affecting 600 roles through reductions or shifts [6] - A related charge of approximately $175 million is anticipated, with the Ascend program expected to deliver $200 to $250 million in adjusted EBITDA savings by 2030, with about 30% achieved in 2026 [6] - The initiative positions Elanco for durable, profitable growth with continued margin expansion and strong cash generation into the latter half of the decade [7] Analyst Insights - Analysts noted initial details on over 15 projects in key areas, including five to six blockbusters, positioning Elanco for three waves of innovation over the next decade [9] - If Elanco successfully executes its pipeline, it is expected to deliver upside to its long-term financial targets [9] - Elanco shares were trading at 21 times the 2026 EPS estimate, with an Outperform rating maintained by analysts [10]

Your portfolio’s fate will likely hinge on 2–3 stocks. The secret is giving them decades to prove it. ...

Portfolio view works with any wallet, and also has support for Solana assetsVisit Uniswap Web App and click the Portfolio tab 🦄https://t.co/liqYXtQWBA ...

Portfolio view works with any wallet, and also has support for Solana assetsVisit Uniswap Web App and click the Portfolio tab 🦄https://t.co/liqYXtQWBA ...

In my opinion, one of the best ecosystems to be looking at to be accumulating in your portfolio, and that's why I hold it in my #Altcoin portfolio: $TAO.The halving is literally around the corner, it's on a higher timeframe support and the ecosystem keeps on expanding. https://t.co/YHsAS7gQv5 ...

30 days to 2026where’s your portfolio standing: up, down, or coping? ...

How far off are you from your portfolio #ATH?Intern here… only needs a tiny 100X. ...

If you're forced to think of your home as an investment, wouldn't you prefer it to work as hard as the rest of your portfolio?That's why we built Horizon.The $35.7 trillion of U.S. home equity deserves better than 4% annual growth. https://t.co/Ywzu7xArkx ...